Electron IORT
Pancreatic Cancer
ApprovedActive
Key Facts
About Intraop Medical
Intraop Medical is a privately held, commercial-stage company that has been a leader in portable electron beam therapy since 1997. Its core technology, the Mobetron, is a self-shielded, mobile linear accelerator that brings radiation directly to the operating room for IORT and treats non-melanoma skin cancer in a clinic setting. The company is now at the forefront of the emerging FLASH radiotherapy field, with its approved platform being used in multi-institutional clinical trials to investigate the potential of ultra-high dose rate treatment to spare healthy tissue. With over forty units installed globally, Intraop has established a significant clinical footprint in leading cancer centers.
View full company profileTherapeutic Areas
Other Pancreatic Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Ampligen® (rintatolimod) | AIM ImmunoTech | Early Access Program |
| HBM9027 | Harbour BioMed | Phase 1 |
| Small-Molecule Therapeutic | AIkido Labs | Pre-clinical |
| AHPBA IRE Registry | AngioDynamics | Post-Market Registry |
| SIMBs + Immunotherapy | Advanced Microbubbles | Pre-clinical |
| CLS-014 | CLS Therapeutics | Pre-clinical |
| SOMA Platform | Coherence Neuro | Pre-clinical |
| NP-G2-044 | Novita Pharmaceuticals | Phase 2a |
| Pritumumab (PTB) | Nascent Biotech | Phase II (Planned) |
| Pancreatic Cancer Test | Mosaique Diagnostic | Development |
| Iontophoretic System | Continuity Biosciences | Pre-clinical |
| Lixumistat (IM156) | ImmunoMet Therapeutics | Phase 1b |